Ras interference as cancer therapy

Seminars in Cancer Biology

Volumn 13, Issue 4, 2003, Pages 267-273

  Duursma, Anja M ^a   Agami, Reuven ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Antisense; Cancer therapy; FTIs; Ras; RNAi

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISIS 2503; K RAS PROTEIN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETROVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA;

BASE MISPAIRING; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DROSOPHILA MELANOGASTER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE LOCUS; GENETIC TRANSDUCTION; HUMAN; MALIGNANT TRANSFORMATION; MELANOMA; MYELOID LEUKEMIA; NONHUMAN; PHENOTYPE; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; RNA INTERFERENCE; ANIMAL; GENE THERAPY; METHODOLOGY; NEOPLASM; ONCOGENE RAS;

ANIMALS; GENE THERAPY; GENES, RAS; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 0642307769     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00040-3     Document Type: Article

References (55)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
2. Bos J.L. All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral. EMBO J. 17:1998;6776-6782.
3. Buday L., Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell. 73:1993;611-620.
4. Rozakis-Adcock M., Fernley R., Wade J., Pawson T., Bowtell D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSos1. Nature. 363:1993;83-85.
5. Bollag G., McCormick F. Differential regulation of rasGAP and neurofibromatosis gene product activities. Nature. 351:1991;576-579.
6. Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 104:2001;593-604.
7. Zhang X.F., Settleman J., Kyriakis J.M., Takeuchi-Suzuki E., Elledge S.J., Marshall M.S.et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature. 364:1993;308-313.
8. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., Der C.J. Increasing complexity of Ras signaling. Oncogene. 17:1998;1395-1413.
9. Robinson M.J., Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:1997;180-186.
10. Johnson G.L., Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 298:2002;1911-1912.
11. Marshall C.J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 80:1995;179-185.
12. Rodriguez-Viciana P., Warne P.H., Dhand R., Vanhaesebroeck B., Gout I., Fry M.J.et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 370:1994;527-532.
13. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 10:1998;262-267.
14. Kikuchi A., Demo S.D., Ye Z.H., Chen Y.W., Williams L.T. ralGDS family members interact with the effector loop of ras p21. Mol. Cell Biol. 14:1994;7483-7491.
15. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: it ain't over 'til it's over'. Trends Cell Biol. 10:2000;147-154.
16. De Ruiter N.D., Burgering B.M., Bos J.L. Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol. Cell Biol. 21:2001;8225-8235.
17. Hamad N.M., Elconin J.H., Karnoub A.E., Bai W., Rich J.N., Abraham R.T. et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16:2002;2045-2057.
18. Boettner B., Van Aelst L. The RASputin effect. Genes Dev. 16:2002;2033-2038.
19. Barbacid M. ras genes. Annu. Rev. Biochem. 56:1987;779-827.
20. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
21. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.
22. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A.et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:2001;1111-1116.
23. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J.et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
24. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R.et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:2001;3243-3248.
25. Meuwissen R., Linn S.C., van der Valk M., Mooi W.J., Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene. 20:2001;6551-6558.
26. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
27. Glomset J.A., Farnsworth C.C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10:1994;181-205.
28. Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. U.S.A. 87:1990;3042-3046.
29. Kato K., Cox A.D., Hisaka M.M., Graham S.M., Buss J.E., Der C.J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. U.S.A. 89:1992;6403-6407.
30. Kohl N.E., Mosser S.D., deSolms S.J., Giuliani E.A., Pompliano D.L., Graham S.L.et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
31. Nagasu T., Yoshimatsu K., Rowell C., Lewis M.D., Garcia A.M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55:1995;5310-5314.
32. Cortes J.E., Albitar M., Thomas D., Giles F., Kurzrock R., Thibault A.et al. Efficacy of the farnesyl transferase inhibitor, R115777, in chronic myeloid leukemia and other hematological malignancies. Blood. 101:2003;1692-1697.
33. Haluska P., Dy G.K., Adjei A.A. Farnesyl transferase inhibitors as anticancer agents. Eur. J. Cancer. 38:2002;1685-1700.
34. Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I., James L., Catino J.J.et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272:1997;14459-14464.
35. Sepp-Lorenzino L., Ma Z., Rands E., Kohl N.E., Gibbs J.B., Oliff A.et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
36. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell Biol. 19:1999;1831-1840.
37. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;672-683.
38. Gray G.D., Hernandez O.M., Hebel D., Root M., Pow-Sang J.M., Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res. 53:1993;577-580.
39. Georges R.N., Mukhopadhyay T., Zhang Y., Yen N., Roth J.A. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res. 53:1993;1743-1746.
40. Dias N., Stein C.A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1:2002;347-355.
41. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:1998;806-811.
42. Sharp P.A. RNA interference - 2001. Genes Dev. 15:2001;485-490.
43. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
44. Bass B.L. RNA interference. The short answer. Nature. 411:2001;428-429.
45. Hannon G.J. RNA interference. Nature. 418:2002;244-251.
46. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
47. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:2002;948-958.
48. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:2002;243-247.
49. Johnson L., Greenbaum D., Cichowski K., Mercer K., Murphy E., Schmitt E.et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11:1997;2468-2481.
50. Koera K., Nakamura K., Nakao K., Miyoshi J., Toyoshima K., Hatta T.et al. K-ras is essential for the development of the mouse embryo. Oncogene. 15:1997;1151-1159.
51. Gitlin L., Karelsky S., Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature. 418:2002;430-434.
52. Jacque J.M., Triques K., Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature. 418:2002;435-438.
53. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K.et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8:2002;681-686.
54. Lewis D.L., Hagstrom J.E., Loomis A.G., Wolff J.A., Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32:2002;107-108.
55. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., Kay M.A. RNA interference in adult mice. Nature. 418:2002;38-39.